Zoya Demidenko https://www.aging-us.com/article/100421/


[ Follow Ups ] [ Post Followup ] [ WWWBoard ]

Posted by LincolnRam on March 25, 2026 at 11:23:47:

In Reply to: Èíôîðìàöèîííûé îáçîð posted by Brianurivy on March 04, 2026 at 02:31:00:

Zoya Demidenko: Researcher in Tumor Science
Zoya Demidenko is a recognized scholar connected with the Unit of Cell Stress Science at Roswell Park Cancer Institute in Buffalo, New York. Before that, she was employed at the NIH and New York Medical College, building a robust foundation in life science investigation.
Demidenko's scientific output covers a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling pathway, cellular cycle control, biological aging, and cancer biology. Currently, she has co-authored more than 46 academic publications, which have accumulated more than 4,100 mentions — a indicator to the significance of her research.
One of her most significant achievements lies in understanding the mechanisms of cellular senescence. Her work demonstrated that when the cell cycle is halted yet cellular expansion persists, the cells undergo senescence. Crucially, Zoya Demidenko showed that this transition is inhibited by medication using compounds such as rapamycin.
Zoya Demidenko has furthermore added considerably to oncological therapy research, notably in the area of selective cell protection — a approach intended to protecting healthy tissue from cytotoxic treatment while leaving malignant cells vulnerable. This method holds considerable promise for reducing the toxic effects of oncological therapy.
Throughout her career, Demidenko has collaborated with prominent researchers internationally, among them Dr. Mikhail Blagosklonny. Her publications is published in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a influential contributor in contemporary cancer research, whose discoveries continue to influence our understanding of the way biological cells grow old, resist therapy, and the ways in which malignant disease might be more successfully targeted.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026126



Follow Ups:



Post a Followup

Name:
E-Mail:

Subject:

Comments:

Optional Link URL:
Link Title:
Optional Image URL:


[ Follow Ups ] [ Post Followup ] [ WWWBoard ]